Pulmonary Vascular Disease News

The combination of a D-dimer level below 1,000 ng/mL and low clinical pretest probability correctly identified a group of patients at low risk for pulmonary embolism during follow-up, according to results of a prospective study published in The New England Journal of Medicine.

LAS VEGAS — In the EXTRACT-PE trial, an aspiration mechanical thrombectomy device was safe and effective among patients with acute pulmonary embolism, researchers reported at VIVA 19.

NEW ORLEANS — Patients with pulmonary fibrosis who are at risk for pulmonary hypertension experienced improvements in physical activity after treatment with inhaled nitric oxide, according to a study presented at the CHEST Annual Meeting.

NEW ORLEANS — New real-world data demonstrate safety and effectiveness of macitentan for the treatment of pulmonary arterial hypertension associated with systemic sclerosis, with outcomes consistent with those in idiopathic and heritable PAH, researchers reported at the CHEST Annual Meeting.

NEW ORLEANS — In a new study, hospital readmission rates for pulmonary embolism were increased for active smokers compared with nonsmokers.

NEW ORLEANS — Initial combination therapy with macitentan and tadalafil yielded hemodynamic and functional improvements and treatment was well tolerated in adults with newly diagnosed pulmonary arterial hypertension, according to data from the OPTIMA study.

Regardless of the surgery type, the risk of postoperative pulmonary embolism was elevated at more than 6 weeks postoperatively, according to published results.

Interventional devices for treatment of acute pulmonary embolism do not have a high level of evidence, and stakeholders must generate more evidence, according to a scientific statement published by the American Heart Association.

In September, the FDA approved the first treatment for a rare pulmonary disease, issued warnings for patients, providers and manufacturers and stepped up its efforts to investigate the outbreak of lung injuries related to the use of electronic cigarettes.

Among patients with idiopathic interstitial pneumonia associated with pulmonary hypertension, treatment with riociguat was linked to an increase in adverse events with no significant evidence of benefit, according to the RISE-IIP trial.